TEVA Teva Pharma Industries Ltd
Company Analysis
Latest News
Teva Pharma Industries Ltd Q2 2026 Earnings Preview: What Analysts Expect on July 29, 2026
Teva Pharma is expected to report Q2 2026 consensus revenue of $4.07 billion and non-GAAP EPS of $0.41, with its stock currently trading at $30.81,...
Teva Licenses Ocrevus Biosimilar, Pivoting Toward High-Margin Specialty Medicines
Teva Pharmaceutical Industries signed a global licensing agreement with Polpharma Biologics for a biosimilar candidate to Ocrevus. This treatment targets...
🔴 TEVA is trading 4.1% down today despite positive vitiligo program update, amidst macro-driven pressure
TEVA is trading 4.1% down at $33.24 today, as broader macro-driven weakness in the pharmaceutical sector weighs on investor sentiment, despite positive news...
Teva Pharma Industries Ltd Q1 2026 Earnings Preview: What Analysts Expect on May 13, 2026
Analysts expect Teva Pharma Industries to report Q1 2026 revenue of $3.87 billion and non-GAAP EPS of $0.55, with the stock currently priced at $36.10, roughly...
Teva's first quarter 2026 revenue of $4.0B beats estimates, driven by 41% AUSTEDO growth.
Teva reported first quarter revenue of approximately $4.0 billion and non-GAAP EPS of $0.53, slightly beating analyst expectations. The results were driven by...
Teva Pharma Industries Ltd Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
Analysts expect Teva to report Q1 2026 revenue of $3.92 billion and adjusted EPS of $0.52, while the current share price of $30.64 remains well below the...